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There	 is	 an	 increasing	 body	 of	 evidence	 that	 the	 overall	 long-term	 survival	 of	 patients	with	 oligometastatic	 non–small	 cell	 lung	 cancer	 (NSCLC)	 exceeds	 survival	 of	 patients	with	 stage	 IV	 disease	 if	 all
detectable	disease	is	ablated.1	Depending	on	the	definition	of	oligometastatic	disease	(OMD)	with	numbers	of	metastases	between	1	and	5,	the	real	incidence	is	not	clear	and	reports	range	from	16%	to	26%.2,3	The
differentiation	of	this	patient	group	from	conventional	stage	IV	patients	might	be	based	on	a	biologically	different,	more	localized	state	of	metastatic	disease,	but	also	the	fact	that	advanced	radiation	techniques,










trials	 (as	 is	 planned).	 It	will	 be	 important	 for	 future	 trials	 to	 precisely	 define	OMD	 and	 its	 subclassification—meta-	 or	 synchronous	 and	 differentiation	 from	 oligo	 recurrence	 and	 oligo	 progression12—	 to	 obtain
comparable	results	and	be	based	on	innovative	biomarkers	aimed	at	facilitating	unbiased	treatment	allocation,	in	particular	in	the	evolving	field	of	immunotherapy	as	a	substantial	pillar	in	the	treatment	of	stage	IV
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